<!DOCTYPE html>
<html class="client-nojs" lang="en" dir="ltr">
<head>
<meta charset="UTF-8"/>
<title>Cyclodestructive Procedures in Treatment of Glaucoma - EyeWiki</title>
<script>document.documentElement.className="client-js";RLCONF={"wgBreakFrames":!1,"wgSeparatorTransformTable":["",""],"wgDigitTransformTable":["",""],"wgDefaultDateFormat":"mdy","wgMonthNames":["","January","February","March","April","May","June","July","August","September","October","November","December"],"wgRequestId":"ZAVjVV6tjNjL7wjQQAjDAwAAAAE","wgCSPNonce":!1,"wgCanonicalNamespace":"","wgCanonicalSpecialPageName":!1,"wgNamespaceNumber":0,"wgPageName":"Cyclodestructive_Procedures_in_Treatment_of_Glaucoma","wgTitle":"Cyclodestructive Procedures in Treatment of Glaucoma","wgCurRevisionId":69808,"wgRevisionId":69808,"wgArticleId":1036,"wgIsArticle":!0,"wgIsRedirect":!1,"wgAction":"view","wgUserName":null,"wgUserGroups":["*"],"wgCategories":["Articles","Glaucoma"],"wgPageContentLanguage":"en","wgPageContentModel":"wikitext","wgRelevantPageName":"Cyclodestructive_Procedures_in_Treatment_of_Glaucoma","wgRelevantArticleId":1036,"wgIsProbablyEditable":!1,
"wgRelevantPageIsProbablyEditable":!1,"wgRestrictionEdit":[],"wgRestrictionMove":[],"sdgDownArrowImage":"/w/extensions/SemanticDrilldown/skins/down-arrow.png","sdgRightArrowImage":"/w/extensions/SemanticDrilldown/skins/right-arrow.png","wgCiteDrawerEnableDesktop":!1,"wgCiteDrawerEnableMobile":!0,"wgCiteDrawerTheme":"dark","wgPageFormsTargetName":null,"wgPageFormsAutocompleteValues":[],"wgPageFormsAutocompleteOnAllChars":!1,"wgPageFormsFieldProperties":[],"wgPageFormsCargoFields":[],"wgPageFormsDependentFields":[],"wgPageFormsCalendarValues":[],"wgPageFormsCalendarParams":[],"wgPageFormsCalendarHTML":null,"wgPageFormsGridValues":[],"wgPageFormsGridParams":[],"wgPageFormsContLangYes":null,"wgPageFormsContLangNo":null,"wgPageFormsContLangMonths":[],"wgPageFormsHeightForMinimizingInstances":800,"wgPageFormsShowOnSelect":[],"wgPageFormsScriptPath":"/w/extensions/PageForms","edgValues":[],"wgPageFormsEDSettings":null,"wgAmericanDates":!0,"wgVisualEditor":{"pageLanguageCode":"en"
,"pageLanguageDir":"ltr","pageVariantFallbacks":"en"},"srfFilteredConfig":null,"wgEditSubmitButtonLabelPublish":!1};RLSTATE={"site.styles":"ready","noscript":"ready","user.styles":"ready","user":"ready","user.options":"loading","ext.cite.styles":"ready","mediawiki.ui.button":"ready","skins.chameleon":"ready","zzz.ext.bootstrap.styles":"ready","mediawiki.toc.styles":"ready","ext.CookieWarning.styles":"ready","oojs-ui-core.styles":"ready","oojs-ui.styles.indicators":"ready","mediawiki.widgets.styles":"ready","oojs-ui-core.icons":"ready","ext.visualEditor.desktopArticleTarget.noscript":"ready","ext.srf.styles":"ready","ext.smw.style":"ready","ext.smw.tooltip.styles":"ready"};RLPAGEMODULES=["ext.smw.style","ext.smw.tooltips","ext.cite.ux-enhancements","smw.entityexaminer","site","mediawiki.page.startup","mediawiki.page.ready","mediawiki.toc","ext.citedrawer.main","ext.CookieWarning","ext.visualEditor.desktopArticleTarget.init","ext.visualEditor.targetLoader","ext.eyeWiki",
"ext.eyeWiki.slideshow","sentry.init","ext.bootstrap.scripts"];</script>
<script>(RLQ=window.RLQ||[]).push(function(){mw.loader.implement("user.options@1hzgi",function($,jQuery,require,module){/*@nomin*/mw.user.tokens.set({"patrolToken":"+\\","watchToken":"+\\","csrfToken":"+\\"});
});});</script>
<link rel="stylesheet" href="/w/load.php?lang=en&amp;modules=ext.CookieWarning.styles%7Cext.cite.styles%7Cext.visualEditor.desktopArticleTarget.noscript%7Cmediawiki.toc.styles%7Cmediawiki.ui.button%7Cmediawiki.widgets.styles%7Coojs-ui-core.icons%2Cstyles%7Coojs-ui.styles.indicators%7Cskins.chameleon%7Czzz.ext.bootstrap.styles&amp;only=styles&amp;skin=chameleon"/>
<link rel="stylesheet" href="/w/load.php?lang=en&amp;modules=ext.smw.style%7Cext.smw.tooltip.styles&amp;only=styles&amp;skin=chameleon"/>
<link rel="stylesheet" href="/w/load.php?lang=en&amp;modules=ext.srf.styles&amp;only=styles&amp;skin=chameleon"/>
<script async="" src="/w/load.php?lang=en&amp;modules=startup&amp;only=scripts&amp;raw=1&amp;skin=chameleon"></script>
<style>#mw-indicator-mw-helplink {display:none;}</style>
<meta name="ResourceLoaderDynamicStyles" content=""/>
<link rel="stylesheet" href="/w/load.php?lang=en&amp;modules=site.styles&amp;only=styles&amp;skin=chameleon"/>
<meta name="generator" content="MediaWiki 1.35.8"/>
<meta name="description" content="Destruction of the ciliary body has been used to treat glaucoma since the 1930s&amp;#91;1&amp;#93;. In cyclodestructive procedures, the secretory epithelium of the ciliary epithelium is damaged, which leads to reduced aqueous humor secretion and lower IOP. Because the ciliary epithelium can regenerate, multiple treatments are  necessary in some patients to achieve the desired long term IOP lowering effect."/>
<meta name="date" content="2019-06-10"/>
<meta name="WT.seg_1" content="0"/>
<meta name="google-site-verification" content="mtQvMIGqpWB4oyYM5mux15MHU-3qWI0bWtyRa2b5rlk"/>
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"/>
<link rel="alternate" type="application/rdf+xml" title="Cyclodestructive Procedures in Treatment of Glaucoma" href="/w/index.php?title=Special:ExportRDF/Cyclodestructive_Procedures_in_Treatment_of_Glaucoma&amp;xmlmime=rdf"/>
<link rel="shortcut icon" href="/w/extensions/EyeWiki/favicons/favicon.ico"/>
<link rel="search" type="application/opensearchdescription+xml" href="/w/opensearch_desc.php" title="EyeWiki (en)"/>
<link rel="EditURI" type="application/rsd+xml" href="https://eyewiki.org/w/api.php?action=rsd"/>
<link rel="preconnect" href="https://fonts.gstatic.com">
<link href="https://fonts.googleapis.com/css2?family=Lato:ital,wght@0,400;0,700;1,400&display=swap" rel="stylesheet">
<!-- Favicons MEYE-108 -->
<link rel="apple-touch-icon" sizes="120x120" href="/w/extensions/EyeWiki/favicons/apple-touch-icon.png">
<link rel="icon" type="image/png" sizes="32x32" href="/w/extensions/EyeWiki/favicons/favicon-32x32.png">
<link rel="icon" type="image/png" sizes="16x16" href="/w/extensions/EyeWiki/favicons/favicon-16x16.png">
<link rel="manifest" href="/w/extensions/EyeWiki/favicons/site.webmanifest">
<link rel="mask-icon" href="/w/extensions/EyeWiki/favicons/safari-pinned-tab.svg" color="#603cba">
<link rel="shortcut icon" href="/w/extensions/EyeWiki/favicons/favicon.ico">
<meta name="msapplication-TileColor" content="#603cba">
<meta name="msapplication-config" content="/w/extensions/EyeWiki/favicons/browserconfig.xml">
<meta name="theme-color" content="#ffffff">
<script> window.interdeal = { "sitekey": "81c701489fb8bb4ab90ca1cb0931f9c5", "Position": "Left", "Menulang": "EN", "domains": { "js": "https://cdn.equalweb.com/", "acc": "https://access.equalweb.com/" }, "btnStyle": { "vPosition": [ "80%", null ], "scale": [ "0.8", "0.8" ], "color": { "main": "#1876c9" }, "icon": { "type": 1, "outline": false } } }; (function(doc, head, body){ var coreCall = doc.createElement('script'); coreCall.src = 'https://cdn.equalweb.com/core/4.3.8/accessibility.js'; coreCall.defer = true; coreCall.integrity = 'sha512-u6i35wNTfRZXp0KDwSb3TntaIKI2ItCt/H/KcYIsBeVbaVMerEQLBnU5/ztfBg9aSW1gg7AN4CqCu9a455jkUg=='; coreCall.crossOrigin = 'anonymous'; coreCall.setAttribute('data-cfasync', true ); body? body.appendChild(coreCall) : head.appendChild(coreCall); })(document, document.head, document.body); </script>
<!--[if lt IE 9]><script src="/w/resources/lib/html5shiv/html5shiv.js"></script><![endif]-->
</head>
<body class="mediawiki ltr sitedir-ltr mw-hide-empty-elt ns-0 ns-subject page-Cyclodestructive_Procedures_in_Treatment_of_Glaucoma rootpage-Cyclodestructive_Procedures_in_Treatment_of_Glaucoma layout-standard skin-chameleon action-view">
	<div class="flex-fill container">
		<div class="row">
			<div class="flex-grow-0 col-12 col-cmln-6 d-flex flex-column flex-md-row w-md-100 justify-content-start align-items-center col">
					<div class="float-left mr-3 mb-2"><a href="//aao.org"><img id="aao-logo" src="/w/extensions/EyeWiki/skins/chameleon/AAO_Logo.png"></a></div>
                		
				<!-- logo and main page link -->
				<div id="p-logo" class="p-logo" role="banner">
					<a href="/Main_Page" title="Visit the main page"><img src="/w/extensions/EyeWiki/skins/chameleon/EyeWiki_Logo.png" alt="EyeWiki"/></a>
				</div>
			</div>
			<div class="ml-auto col-12 col-cmln col">
				<div class="row">
					<div class="col">
						<!-- personal tools -->
						<div class="p-personal pull-right" id="p-personal" >
							<ul class="p-personal-tools" >
								<li id="pt-createaccount"><a href="/w/index.php?title=Special:CreateAccount&amp;returnto=Cyclodestructive+Procedures+in+Treatment+of+Glaucoma" title="You are encouraged to create an account and log in; however, it is not mandatory" class="pt-createaccount">Create account</a></li>
								<li id="pt-login"><a href="/w/index.php?title=Special:UserLogin&amp;returnto=Cyclodestructive+Procedures+in+Treatment+of+Glaucoma" title="You are encouraged to log in; however, it is not mandatory [o]" accesskey="o" class="pt-login">Log in</a></li>
							</ul>
						</div>

					</div>
				</div>
				<div class="row">
					<div class="col">
						<!-- search form -->
						<div  id="p-search" class="p-search pull-right" role="search"  >
							<form  id="searchform" class="mw-search" action="/w/index.php" >
								<input type="hidden" name="title" value=" Special:Search" />
								<div class="input-group">
									<input name="search" placeholder="Search EyeWiki" title="Search EyeWiki [f]" accesskey="f" id="searchInput" class="form-control"/>
									<div class="input-group-append">
										<button value="Go" id="searchGoButton" name="go" type="submit" class="search-btn searchGoButton" aria-label="Go to page" title="Go to a page with this exact name if it exists"></button>
									</div>
								</div>
							</form>
						</div>
					</div>
				</div>
			</div>
		</div>
		<div class="row">
			<div class="col">
				<!-- navigation bar -->
				<nav class="p-navbar collapsible mb-3 mt-2 p-1 mt-cmln-0" role="navigation" id="mw-navigation">
					<button type="button" class="navbar-toggler" data-toggle="collapse" data-target="#hbpzysj58t"></button>
					<div class="collapse navbar-collapse hbpzysj58t" id="hbpzysj58t">
						<div class="navbar-nav"><div class="nav-item"><a class="nav-link fas fa-home"  href="/Main_Page">Main Page</a></div><div class="nav-item"><a class="nav-link fas fa-book"  href="/Category:Articles">Articles</a></div><div class="nav-item"><a class="nav-link fas fa-play"  href="/Help:Getting_Started">Getting Started</a></div><div class="nav-item"><a class="nav-link fas fa-question"  href="/Help:Contents">Help</a></div><div class="nav-item"><a class="nav-link fas fa-backward"  href="/Special:RecentChanges">Recent changes</a></div><div class="nav-item"><a class="nav-link fas fa-door-open"  href="#">My Portal</a></div>
						</div>
					</div>
				</nav>
			</div>
		</div>
		<div class="row">
			<div class="col">
				<!-- Content navigation -->
				<div class="mb-3 pagetools p-contentnavigation" id="p-contentnavigation">
					<!-- namespaces -->
					<div id="p-namespaces" class="p-namespaces">
						<div class="tab-group">
							<div id="ca-nstab-main" class="selected"><a href="/Cyclodestructive_Procedures_in_Treatment_of_Glaucoma" title="View the content page [c]" accesskey="c" class="selected ca-nstab-main">Page</a></div>
							<div id="ca-talk" class="new"><a href="/w/index.php?title=Talk:Cyclodestructive_Procedures_in_Treatment_of_Glaucoma&amp;action=edit&amp;redlink=1" rel="discussion" title="Discussion about the content page (page does not exist) [t]" accesskey="t" class="new ca-talk">Discussion</a></div>
						</div>
					</div>
					<!-- views -->
					<div id="p-views" class="p-views">
						<div class="tab-group">
							<div id="ca-formedit"><a href="/w/index.php?title=Cyclodestructive_Procedures_in_Treatment_of_Glaucoma&amp;action=formedit" title="Edit this page with a form [&amp;]" accesskey="&amp;" class="ca-formedit">View form</a></div>
							<div id="ca-viewsource"><a href="/w/index.php?title=Cyclodestructive_Procedures_in_Treatment_of_Glaucoma&amp;action=edit" title="This page is protected.&#10;You can view its source [e]" accesskey="e" class="ca-viewsource">View source</a></div>
							<div id="ca-history"><a href="/w/index.php?title=Cyclodestructive_Procedures_in_Treatment_of_Glaucoma&amp;action=history" title="Past revisions of this page [h]" accesskey="h" class="ca-history">History</a></div>
						</div>
					</div>
				</div>
			</div>
		</div>
		<div class="row">
			<div class="col-auto mx-auto col">

			</div>
		</div>
		<div class="row">
			<div class="col-auto mx-auto col">
			</div>
		</div>
		<div class="row">
			<div class="col">
				<!-- start the content area -->
				<div id="content" class="mw-body content"><a id="top" class="top"></a>
					<div id="mw-indicators" class="mw-indicators">
					<div id="mw-indicator-smw-entity-examiner" class="mw-indicator mw-indicator-smw-entity-examiner"><div class="smw-entity-examiner smw-indicator-vertical-bar-loader" data-subject="Cyclodestructive_Procedures_in_Treatment_of_Glaucoma#0##" data-dir="ltr" data-uselang="" title="Running an examiner in the background"></div></div>
				</div>
						<div class="contentHeader">
						<!-- title of the page -->
						<h1 id="firstHeading" class="firstHeading">Cyclodestructive Procedures in Treatment of Glaucoma</h1>
						<!-- tagline; usually goes something like "From WikiName" primary purpose of this seems to be for printing to identify the source of the content -->
						<div id="siteSub" class="siteSub">From EyeWiki</div><div id="jump-to-nav" class="mw-jump jump-to-nav">Jump to:<a href="#mw-navigation">navigation</a>, <a href="#p-search">search</a></div>
					</div>
					<div id="bodyContent" class="bodyContent">
						<!-- body text -->

						<div id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><div class="mw-parser-output"><div id="article-header" data-description2-ignore=""><div id="contest" style="margin-bottom: 6px;">
</div>
<div class="infobox contributors">
<div class="info-section" style="margin-bottom: 10px;">
<div class="info-section-header"><a href="/Property:Authors" title="Property:Authors">Article initiated by</a>:
</div>
<div class="info-section-body"><a href="/User:Babak.Eliassi-Rad" title="User:Babak.Eliassi-Rad">Babak Eliassi-Rad, MD</a>
</div>
</div>
<div class="info-section" style="margin-bottom: 10px;">
<div class="info-section-header">All authors and contributors:
</div>
<div class="info-section-body"> <a href="/User:Anjana.P.Jindal.CMT" title="User:Anjana.P.Jindal.CMT">Anjana P. Jindal</a>,&#160;<a href="/User:Ahmad.A.Aref" title="User:Ahmad.A.Aref">Ahmad A. Aref, MD, MBA</a>,&#160;<a href="/User:JoAnn.A.Giaconi.CMT" title="User:JoAnn.A.Giaconi.CMT">JoAnn A. Giaconi, MD</a>,&#160;<a href="/User:Babak.Eliassi-Rad" title="User:Babak.Eliassi-Rad">Babak Eliassi-Rad, MD</a>
</div>
</div>
<div class="info-section" style="margin-bottom: 10px;">
<div class="info-section-header">Assigned editor:
</div>
<div class="info-section-body"> <a href="/User:Ian.Conner" title="User:Ian.Conner">Ian Conner, MD, PhD</a></div>
</div><div class="info-section" style="margin-bottom: 10px;">
<div class="info-section-header">Review:
</div>
<div class="info-section-body">Assigned status <b>Update Pending</b>
</div>
</div>&#160;by <a href="/User:Ahmad.A.Aref" title="User:Ahmad.A.Aref">Ahmad A. Aref, MD, MBA</a> on June 11, 2019.
</div>
<div style="display:none;">
<table cellspacing="5">

<tbody><tr>
<td><small><a rel="nofollow" class="external text" href="https://eyewiki.org/w/index.php?title=Cyclodestructive_Procedures_in_Treatment_of_Glaucoma&amp;action=formedit">add</a></small>
</td></tr>
<tr>
<th align="right"><b><a href="/Property:Contributing_Editors" title="Property:Contributing Editors">Contributing Editors</a>:</b>
</th>
<td><small><a rel="nofollow" class="external text" href="https://eyewiki.org/w/index.php?title=Cyclodestructive_Procedures_in_Treatment_of_Glaucoma&amp;action=formedit">add</a></small>
</td></tr>
</tbody></table></div>
<div style="display:none;">
<p><br />
</p>
</div>
<div id="local-videos">
</div>
</div>
<div id="toc" class="toc" role="navigation" aria-labelledby="mw-toc-heading"><input type="checkbox" role="button" id="toctogglecheckbox" class="toctogglecheckbox" style="display:none" /><div class="toctitle" lang="en" dir="ltr"><h2 id="mw-toc-heading">Contents</h2><span class="toctogglespan"><label class="toctogglelabel" for="toctogglecheckbox"></label></span></div>
<ul>
<li class="toclevel-1 tocsection-1"><a href="#Introduction"><span class="tocnumber">1</span> <span class="toctext">Introduction</span></a>
<ul>
<li class="toclevel-2 tocsection-2"><a href="#Indications"><span class="tocnumber">1.1</span> <span class="toctext">Indications</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-3"><a href="#Surgical_Technique"><span class="tocnumber">2</span> <span class="toctext">Surgical Technique</span></a>
<ul>
<li class="toclevel-2 tocsection-4"><a href="#Diode_TS-CPC"><span class="tocnumber">2.1</span> <span class="toctext">Diode TS-CPC</span></a></li>
<li class="toclevel-2 tocsection-5"><a href="#Endocyclophotocoagulation_.28ECP.29"><span class="tocnumber">2.2</span> <span class="toctext">Endocyclophotocoagulation (ECP)</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-6"><a href="#Management"><span class="tocnumber">3</span> <span class="toctext">Management</span></a></li>
<li class="toclevel-1 tocsection-7"><a href="#Complications"><span class="tocnumber">4</span> <span class="toctext">Complications</span></a>
<ul>
<li class="toclevel-2 tocsection-8"><a href="#TS-CPC"><span class="tocnumber">4.1</span> <span class="toctext">TS-CPC</span></a></li>
<li class="toclevel-2 tocsection-9"><a href="#ECP"><span class="tocnumber">4.2</span> <span class="toctext">ECP</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-10"><a href="#Clinical_outcomes"><span class="tocnumber">5</span> <span class="toctext">Clinical outcomes</span></a>
<ul>
<li class="toclevel-2 tocsection-11"><a href="#TS-CPC_2"><span class="tocnumber">5.1</span> <span class="toctext">TS-CPC</span></a></li>
<li class="toclevel-2 tocsection-12"><a href="#ECP_2"><span class="tocnumber">5.2</span> <span class="toctext">ECP</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-13"><a href="#Conclusion"><span class="tocnumber">6</span> <span class="toctext">Conclusion</span></a></li>
<li class="toclevel-1 tocsection-14"><a href="#References"><span class="tocnumber">7</span> <span class="toctext">References</span></a></li>
</ul>
</div>

<h1><span class="mw-headline" id="Introduction">Introduction</span></h1>
<p>Destruction of the ciliary body has been used to treat glaucoma since the 1930s<sup id="cite_ref-vogt1_1-0" class="reference"><a href="#cite_note-vogt1-1">&#91;1&#93;</a></sup>. In cyclodestructive procedures, the secretory epithelium of the ciliary epithelium is damaged, which leads to reduced aqueous humor secretion and lower IOP. Because the ciliary epithelium can regenerate, multiple treatments are  necessary in some patients to achieve the desired long term IOP lowering effect. 
</p><p>The different modalities to achieve cyclodestruction are: diathermy<sup id="cite_ref-vogt1_1-1" class="reference"><a href="#cite_note-vogt1-1">&#91;1&#93;</a></sup>, surgical excision, cryotherapy<sup id="cite_ref-:2_2-0" class="reference"><a href="#cite_note-:2-2">&#91;2&#93;</a></sup>, ultrasound<sup id="cite_ref-:3_3-0" class="reference"><a href="#cite_note-:3-3">&#91;3&#93;</a></sup>, and laser light<sup id="cite_ref-beckman4_4-0" class="reference"><a href="#cite_note-beckman4-4">&#91;4&#93;</a></sup> <sup id="cite_ref-:5_5-0" class="reference"><a href="#cite_note-:5-5">&#91;5&#93;</a></sup>. Cyclophotocoagulation (CPC) is the most common procedure to perform cyclodestruction. It can be performed using  different laser wavelengths. CPC was first performed by Beckman et al.<sup id="cite_ref-beckman4_4-1" class="reference"><a href="#cite_note-beckman4-4">&#91;4&#93;</a></sup> using a ruby laser (693 nm wavelength). Neodymium:yttrium-aluminum-garnet (Nd:YAG) laser (1064 nm wavelength)<sup id="cite_ref-:6_6-0" class="reference"><a href="#cite_note-:6-6">&#91;6&#93;</a></sup> <sup id="cite_ref-:7_7-0" class="reference"><a href="#cite_note-:7-7">&#91;7&#93;</a></sup> <sup id="cite_ref-:8_8-0" class="reference"><a href="#cite_note-:8-8">&#91;8&#93;</a></sup> has been used either with non-contact or contact methods to achieve cyclodestruction. Presently, diode laser (810 nm wavelength) either transsceral or with an endoscopic probe is used to perform CPC. The diode laser is preferred over other wavelengths since the melanin in the ciliary epithelium better absorbs this wavelength than others and therefore causes more targeted destruction with less inflammation<sup id="cite_ref-pastor9_9-0" class="reference"><a href="#cite_note-pastor9-9">&#91;9&#93;</a></sup>. 
</p>
<h2><span class="mw-headline" id="Indications">Indications</span></h2>
<p>Transscleral CPC (TS-CPC) and endocylcophotocoagulation (ECP) are performed for similar glaucoma conditions (<a href="#Table1">Table-1</a> and <a href="#Table2">Table-2</a> respectively). In general, TS-CPC and ECP are indicated for refractory glaucoma, or eyes with poor visual acuity or poor visual potential. 
<span id="Table1"></span>
</p>
<table class="wikitable">
<caption>Table-1. Indications for Transcleral Cyclophotocoagulation
</caption>
<tbody><tr>
<td>Elevated IOP with poor vision or poor visual potential
</td></tr>
<tr>
<td>Pain relief due to elevated IOP in a blind painful eye<sup id="cite_ref-:10_10-0" class="reference"><a href="#cite_note-:10-10">&#91;10&#93;</a></sup>
</td></tr>
<tr>
<td>
<p>Uncontrolled glaucoma in the presence of conjunctival scarring from previous surgery 
</p>
</td></tr>
<tr>
<td>Patient's medical condition preclude going to operating room
</td></tr>
<tr>
<td>Patient refuses surgery in operating room
</td></tr>
<tr>
<td>Primary surgical treatment of glaucoma<sup id="cite_ref-egbert11_11-0" class="reference"><a href="#cite_note-egbert11-11">&#91;11&#93;</a></sup>
</td></tr>
<tr>
<td>Primary open-angle glaucoma<sup id="cite_ref-ansari12_12-0" class="reference"><a href="#cite_note-ansari12-12">&#91;12&#93;</a></sup>
</td></tr>
<tr>
<td>Angle-closure glaucoma<sup id="cite_ref-:13_13-0" class="reference"><a href="#cite_note-:13-13">&#91;13&#93;</a></sup>
</td></tr>
<tr>
<td>Neovascular glaucoma<sup id="cite_ref-:14_14-0" class="reference"><a href="#cite_note-:14-14">&#91;14&#93;</a></sup>
</td></tr>
<tr>
<td>Pseudophakic/aphakic glaucoma<sup id="cite_ref-:15_15-0" class="reference"><a href="#cite_note-:15-15">&#91;15&#93;</a></sup>
</td></tr>
<tr>
<td>Pediatric glaucoma<sup id="cite_ref-:16_16-0" class="reference"><a href="#cite_note-:16-16">&#91;16&#93;</a></sup>
</td></tr>
<tr>
<td>Glaucoma after penetrating keratoplasty<sup id="cite_ref-:17_17-0" class="reference"><a href="#cite_note-:17-17">&#91;17&#93;</a></sup>
</td></tr>
<tr>
<td>Uveitic glaucoma<sup id="cite_ref-:18_18-0" class="reference"><a href="#cite_note-:18-18">&#91;18&#93;</a></sup>
</td></tr>
<tr>
<td>Silicone oil induced glaucoma<sup id="cite_ref-:19_19-0" class="reference"><a href="#cite_note-:19-19">&#91;19&#93;</a></sup>
</td></tr></tbody></table>
<p><br />
<span id="Table2"></span>
</p>
<table class="wikitable">
<caption>Table-2. Indications for Endocyclophotocoagulation
</caption>
<tbody><tr>
<td>Patients who are poor candidates for glaucoma filtration surgery or glaucoma drainage implant<sup id="cite_ref-:20_20-0" class="reference"><a href="#cite_note-:20-20">&#91;20&#93;</a></sup>
</td></tr>
<tr>
<td>Primary open-angle glaucoma<sup id="cite_ref-lin21_21-0" class="reference"><a href="#cite_note-lin21-21">&#91;21&#93;</a></sup>
</td></tr>
<tr>
<td>Pseudoexfoliation glaucoma<sup id="cite_ref-lin21_21-1" class="reference"><a href="#cite_note-lin21-21">&#91;21&#93;</a></sup>
</td></tr>
<tr>
<td>Neovascular glaucoma<sup id="cite_ref-lima22_22-0" class="reference"><a href="#cite_note-lima22-22">&#91;22&#93;</a></sup>
</td></tr>
<tr>
<td>Pseudophakic glaucoma<sup id="cite_ref-lima22_22-1" class="reference"><a href="#cite_note-lima22-22">&#91;22&#93;</a></sup>
</td></tr>
<tr>
<td>Glaucoma after penetrating keratoplasty<sup id="cite_ref-lima22_22-2" class="reference"><a href="#cite_note-lima22-22">&#91;22&#93;</a></sup>
</td></tr>
<tr>
<td>Glaucoma associated with retinal surgery<sup id="cite_ref-lima22_22-3" class="reference"><a href="#cite_note-lima22-22">&#91;22&#93;</a></sup>
</td></tr>
<tr>
<td>Pediatric glaucoma<sup id="cite_ref-neely23_23-0" class="reference"><a href="#cite_note-neely23-23">&#91;23&#93;</a></sup><sup id="cite_ref-carter37_24-0" class="reference"><a href="#cite_note-carter37-24">&#91;24&#93;</a></sup>
</td></tr>
<tr>
<td>Angle-closure glaucoma
</td></tr></tbody></table>
<h1><span class="mw-headline" id="Surgical_Technique">Surgical Technique</span></h1>
<h2><span class="mw-headline" id="Diode_TS-CPC">Diode TS-CPC</span></h2>
<p>A semi-conductor solid state diode laser system (Oculight SLx, Iridex Corporation, Mountain View, CA) with a wavelength of 810 nm is used to perform TS-CPC9. A handpiece (G probe, Iridex, Mountain View, CA) is used to deliver the laser energy. Diode TS-CPC can be performed in a minor procedure room or in an operating suite. Retrobulbar or peribulbar anesthesia is needed, as the procedure is painful.   A block consisting of either a 50:50 mixture of lidocaine 2% without epinephrine and bupivacaine 0.75% or straight lidocaine can be given.  A lid speculum helps to provide better exposure to the peri-limbal area. This author uses the following laser parameters: Initial power of 1250 mW and duration of 4 seconds. The power is increased in 150 mW increments until an audible “pop” is heard. The audible “pop” signifies tissue explosion of the ciliary process, the iris root, or the retina<sup id="cite_ref-pastor9_9-1" class="reference"><a href="#cite_note-pastor9-9">&#91;9&#93;</a></sup>. When a “pop” is heard the power is decreased by 150 mW until there is no audible “pop”. The maximum power used is 2250 mW. Others will start at 2000 mW and 2 seconds and titrate the energy down.  Generally 6 spots are used per quadrant for a total of 18 spots. Some surgeons recommend treating only 3 quadrants to avoid anterior segment necrosis, and many recommend sparing the 3:00 and 9:00 positions where the ciliary nerves lie.  After completion of the procedure a topical antibiotic, steroid, and cycloplegic agents are placed on the eye. The eye should be patched after a block is used to protect the cornea. The patient is seen the next day for follow-up. 
</p>
<h2><span id="Endocyclophotocoagulation_(ECP)"></span><span class="mw-headline" id="Endocyclophotocoagulation_.28ECP.29">Endocyclophotocoagulation (ECP)</span></h2>
<p>The ECP laser unit (Endo Optiks, Little Silver, NJ) has 4 different components, the diode laser (pulsed continuous-wave energy at 810 nm), a xenon light source, a helium-neon laser aiming beam, and video monitor and recorder. The probe is 20 gauge with a full view of 110 degrees and depth of focus of 1-30mm. The equipment console consists of the video camera, light source, video monitor, and the video recorder. Initially the laser probe is placed into the anterior chamber by looking through the surgical microscope. Then the surgeon looks through the video monitor to locate the ciliary processes and perform the laser photocoagulation. The goal of each laser application is to whiten and shrink the ciliary process. The entire ciliary process should be treated. Generally 270-360 degrees of the ciliary processes are treated. Gas bubble formation, pigmentary dispersion, audible “pops”, photocoagulation of non-ciliary process tissue should be avoided20. The laser settings are as follows: Power 0.2 W, continuous-wave mode. The power is titrated to achieve whitening and shrinkage of the ciliary process by positioning the probe either closer or further from the processes.  Ideally, 3 processes should be within view during treatment. 
</p><p>ECP can be performed in phakic, pseudophakic, or aphakic eye with the endolaser probe through the limbus or pars plana. In the limbal approach, a 1.5-2.0 mm incision is made in the clear cornea or sclera. A cohesive viscoelastic is injected posterior to the iris and anterior to the lens capsule to deepen the ciliary sulcus space. Next the probe is placed in the anterior chamber. The ciliary processes are visualized and treated. At the end of the procedure, the viscoelastic is removed. In phakic patients great care should be taken not to nick the anterior lens capsule. In pseudophakic/aphakic eyes, the pars plana approach is advantageous since the ciliary processes are better visualized. The incision is made 3.5-4.0mm posterior to the limbus. Anterior vitrectomy is performed, then cyclophotocoagulation with the endolaser probe is performed. ECP can be combined with phacoemulsification to treat cataract and glaucoma at the same time<sup id="cite_ref-neely23_23-1" class="reference"><a href="#cite_note-neely23-23">&#91;23&#93;</a></sup>. In combined cases ECP can be performed before or after inserting the intraocular lens in the lens bag. <a href="/Endoscopic_Cylcophotocoagulation_(ECP)" class="mw-redirect" title="Endoscopic Cylcophotocoagulation (ECP)">Endoscopic Cylcophotocoagulation (ECP)
</a>
</p>
<h1><span class="mw-headline" id="Management">Management</span></h1>
<p>Post-operatively the patient is started on cycloplegics (atropine 1% twice a day for 2 weeks) and topical corticosteroids (prednisolone acetate 1% 4 times a day). If there is extensive anterior chamber inflammation the steroid drops can be applied more frequently. Additionally subtenon’s steroid injection and/or oral steroids can be used. After ECP topical antibiotics are necessary since it is an intraocular procedure. The pre-laser glaucoma medications are continued post-operatively and can be tapered based on the intraocular pressure (IOP) lowering effect of the laser. Miotics should be stopped because they can enhance the inflammatory response and cause posterior synechiae. Consideration should also be given to stopping the prostaglandin analogs if the IOP is well controlled since they can cause anterior chamber inflammation. 
</p>
<h1><span class="mw-headline" id="Complications">Complications</span></h1>
<h2><span class="mw-headline" id="TS-CPC">TS-CPC</span></h2>
<p>Pain is usually transient and controlled with over-the-counter analgesics, although some patients may require prescription strength analgesics.   Hyphema occurs more frequently in neovascular glaucoma patients. Iridocyclitis occurs commonly after TS-CPC. Few patients can develop a chronic low-grade anterior chamber inflammation due to a breakdown in the blood-aqueous barrier. Conjunctival burns are rare, but they can occur if the conjunctival surface becomes dry during laser applications, with high energy settings in cases of darkly pigmented conjunctiva, and due to the use of defective, damaged, or soiled laser probes.  Hypotony has been reported after CPC. In one study<sup id="cite_ref-:24_25-0" class="reference"><a href="#cite_note-:24-25">&#91;25&#93;</a></sup> 5 out of 20 patients with neovascular glaucoma undergoing CPC developed hypotony. In this study, patients who had 2 or more previous pars plana vitrectomies also developed hypotony. Vision loss can occur after TS-CPC<sup id="cite_ref-egbert11_11-1" class="reference"><a href="#cite_note-egbert11-11">&#91;11&#93;</a></sup><sup id="cite_ref-ansari12_12-1" class="reference"><a href="#cite_note-ansari12-12">&#91;12&#93;</a></sup><sup id="cite_ref-:25_26-0" class="reference"><a href="#cite_note-:25-26">&#91;26&#93;</a></sup> (incidence ranging from 13%-50% depending on the study population). Phthisis bulbi is a rare complication of TS-CPC<sup id="cite_ref-:26_27-0" class="reference"><a href="#cite_note-:26-27">&#91;27&#93;</a></sup>. Malignant glaucoma<sup id="cite_ref-:27_28-0" class="reference"><a href="#cite_note-:27-28">&#91;28&#93;</a></sup>, necrotizing scleritis<sup id="cite_ref-:28_29-0" class="reference"><a href="#cite_note-:28-29">&#91;29&#93;</a></sup>, and sympathetic ophthalmia<sup id="cite_ref-:29_30-0" class="reference"><a href="#cite_note-:29-30">&#91;30&#93;</a></sup> <sup id="cite_ref-:30_31-0" class="reference"><a href="#cite_note-:30-31">&#91;31&#93;</a></sup> have been reported after TS-CPC. 
</p>
<h2><span class="mw-headline" id="ECP">ECP</span></h2>
<p>Chen et. al.<sup id="cite_ref-chen31_32-0" class="reference"><a href="#cite_note-chen31-32">&#91;32&#93;</a></sup> performed a retrospective study on 68 eyes that underwent ECP for refractory glaucoma. They reported the following complications: fibrin exudates (24%), hyphema (12%), cystoids edema (10%), vision loss of 2 lines or more (6%). They did not have any cases of phthisis bulbi, endophthalmitis, or sympathetic ophthalmia, which are possible. Traumatic injury to the iris has been reported with ECP<sup id="cite_ref-:32_33-0" class="reference"><a href="#cite_note-:32-33">&#91;33&#93;</a></sup>. This complication is due to laser being improperly applied to the iris or through mechanical trauma. Therefore the surgeon must be aware of the location of the endolaser probe at all times and the laser should only be applied to the ciliary processes. 
</p>
<h1><span class="mw-headline" id="Clinical_outcomes">Clinical outcomes</span></h1>
<h2><span class="mw-headline" id="TS-CPC_2">TS-CPC</span></h2>
<p>TS-CPC has been used in different types of intractable glaucoma (see <a href="#Table1">Table-1</a>). &#160;Rivier et al.<sup id="cite_ref-:33_34-0" class="reference"><a href="#cite_note-:33-34">&#91;34&#93;</a></sup> reported that TS-CPC can be used before or after keratoprosthesis surgery to control the IOP. In their study, the mean IOP was significantly lowered at 6, 12, 24, 36, and 48 months. At the last follow-up visit (mean follow-up: 26.6 months) the mean best-corrected visual acuity and the number of glaucoma medications was stable. Since CME is a complication of TS-CPC, this laser is usually performed in eyes with poor vision and/or poor visual potential. However, recent studies have shown that TS-CPC can be performed in eyes with good vision<sup id="cite_ref-ansari12_12-2" class="reference"><a href="#cite_note-ansari12-12">&#91;12&#93;</a></sup><sup id="cite_ref-rotchford34_35-0" class="reference"><a href="#cite_note-rotchford34-35">&#91;35&#93;</a></sup>. Rotchford et al.<sup id="cite_ref-rotchford34_35-1" class="reference"><a href="#cite_note-rotchford34-35">&#91;35&#93;</a></sup> analyzed TS-CPC in patients with pre-laser visual acuity of 20/60 or better. The median visual acuity before the laser was 20/30 (Range; 20/16-20/60) and the median follow-up was 5 years. 31% of eyes lost 2 or more lines of vision. 67% of eyes retained visual acuity of 20/60 or better and 16% of eyes had a visual acuity less than 20/200. In eyes that lost 2 or more lines of vision, the main cause was glaucoma progression (50%). Other causes were: macular edema, retinal detachment, cataract formation, and macular degeneration. In another study<sup id="cite_ref-ansari12_12-3" class="reference"><a href="#cite_note-ansari12-12">&#91;12&#93;</a></sup>, in a subset of 23 POAG eyes with good vision only 3 eyes had decreased visual acuity at the final visit. In two of these eyes, the decreased vision was due to cataract formation and in one eye reduced vision was due to chronic anterior uveitis and glaucoma progression. TS-CPC has been used has primary surgical treatment for POAG with good results<sup id="cite_ref-egbert11_11-2" class="reference"><a href="#cite_note-egbert11-11">&#91;11&#93;</a></sup>. In this study, the IOP decreased by 20% in 47% of eyes and the IOP was 22 mmHg or less in 48% of eyes. There were no serious complications such as hypotony, phthisis bulbi, or sympathetic ophthalmia. In 77% of eyes the vision remained the same or was better after the laser. 
</p>
<h2><span class="mw-headline" id="ECP_2">ECP</span></h2>
<p>In a study of 68 eyes with refractory glaucoma that underwent ECP, the mean IOP reduced from 27.7mmHg ro 17.0mmHg (34% mean reduction) <sup id="cite_ref-chen31_32-1" class="reference"><a href="#cite_note-chen31-32">&#91;32&#93;</a></sup>. The number of glaucoma medications decreased from 3 to 2. The mean follow-up period was 12.9 months. Ninety percent of eyes had IOP less than 22mmHg at the last follow-up period. ECP was found to be as effective as trabeculectomy in IOP lowering when combined with cataract surgery<sup id="cite_ref-:35_36-0" class="reference"><a href="#cite_note-:35-36">&#91;36&#93;</a></sup>. &#160;In a prospective study, ECP has shown to be effective as Ahmed valve in lowering IOP in eyes with refractory glaucoma. &#160;The frequency of complications was higher in the Ahmed valve group<sup id="cite_ref-lima22_22-4" class="reference"><a href="#cite_note-lima22-22">&#91;22&#93;</a></sup>. ECP has been used in eyes that have had a prior drainage device implant and uncontrolled IOP<sup id="cite_ref-:36_37-0" class="reference"><a href="#cite_note-:36-37">&#91;37&#93;</a></sup>. &#160;In this study 25 eyes with prior history of a glaucoma drainage implant and uncontrolled IOP underwent ECP. At 12 months, the mean IOP dropped from 24mmHg to 15.4mmHg, and mean number of glaucoma medications decreased from 3.2 to 1.5. There were no serious complications. ECP has moderate success rates in aphakic and pseudophakic glaucoma in children<sup id="cite_ref-carter37_24-1" class="reference"><a href="#cite_note-carter37-24">&#91;24&#93;</a></sup>. ECP reduce d the IOP from a mean of 32.6mmHg to 22.9mmHg at last follow-up. The average number of procedures was 1.5. There were 2 cases of retinal detachment. Hypotony was not observed in this study. 
</p>
<h1><span class="mw-headline" id="Conclusion">Conclusion</span></h1>
<p>Both TS-CPC and ECP are safe and effective procedures to control IOP in refractory glaucomas. Recently TS-CPC has been performed in patients with good vision with good results. ECP can be combined with cataract surgery to with good success rates. 
</p>
<h1><span class="mw-headline" id="References">References</span></h1>
<div class="mw-references-wrap mw-references-columns"><ol class="references">
<li id="cite_note-vogt1-1"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-vogt1_1-0">1.0</a></sup> <sup><a href="#cite_ref-vogt1_1-1">1.1</a></sup></span> <span class="reference-text">Vogt A. Versuche zur intraokularen druckherabsetzung mittelst diathermiescha¨digung des corpus ciliare Zyklodiathermiestichelung). Klin Monatsbl Augenheilkd 1936;97:672–3.</span>
</li>
<li id="cite_note-:2-2"><span class="mw-cite-backlink"><a href="#cite_ref-:2_2-0">↑</a></span> <span class="reference-text">Bietti G. Surgical intervention on the ciliary body; new trends for the relief of glaucoma. JAMA 1950;142:889–97.</span>
</li>
<li id="cite_note-:3-3"><span class="mw-cite-backlink"><a href="#cite_ref-:3_3-0">↑</a></span> <span class="reference-text">Coleman DJ, Lizzi FL, Driller J, et al. Therapeutic ultrasound in the treatment of glaucoma. II. Clinical applications. Ophthalmology 1985;92:347–53</span>
</li>
<li id="cite_note-beckman4-4"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-beckman4_4-0">4.0</a></sup> <sup><a href="#cite_ref-beckman4_4-1">4.1</a></sup></span> <span class="reference-text">Beckman H, Kinoshita A, Rota AN, Sugar HS. Transscleral ruby laser irradiation of the ciliary body in the treatment of intractable glaucoma. Trans Am Acad Ophthalmol Otolaryngol 1972;76:423–36</span>
</li>
<li id="cite_note-:5-5"><span class="mw-cite-backlink"><a href="#cite_ref-:5_5-0">↑</a></span> <span class="reference-text">Shields MB. Cyclodestructive surgery for glaucoma: past, present, and future. Trans Am Ophthalmol Soc 1985; 83:285-303</span>
</li>
<li id="cite_note-:6-6"><span class="mw-cite-backlink"><a href="#cite_ref-:6_6-0">↑</a></span> <span class="reference-text">Beckman H, Sugar HS. Neodymium laser cyclophotocoagulation. Arch Ophthalmol 1973; 90:27-8</span>
</li>
<li id="cite_note-:7-7"><span class="mw-cite-backlink"><a href="#cite_ref-:7_7-0">↑</a></span> <span class="reference-text">Brancato R, Giovanni L, Trabucchi G, et al. Contact transscleral cyclophotocoagulation with Nd:YAG laser in uncontrolled glaucoma. Ophthalmic Surg 1989;20:547-51</span>
</li>
<li id="cite_note-:8-8"><span class="mw-cite-backlink"><a href="#cite_ref-:8_8-0">↑</a></span> <span class="reference-text">Schuman JS, Bellows AR, Shingleton BJ, et al. Contact transscleral Nd:YAG laser cyclophotocoagulation. Midterm results. Ophthalmology 1992;99:1089-1094; Discussion 1095</span>
</li>
<li id="cite_note-pastor9-9"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-pastor9_9-0">9.0</a></sup> <sup><a href="#cite_ref-pastor9_9-1">9.1</a></sup></span> <span class="reference-text">Pastor SA, Singh K, Lee DA, et al. Cyclophotocoagulation: A Report by the American Academy of Ophthalmology 2001;108:2130-2138</span>
</li>
<li id="cite_note-:10-10"><span class="mw-cite-backlink"><a href="#cite_ref-:10_10-0">↑</a></span> <span class="reference-text">Martin KR, Broadway DC. Cyclodiode laser therapy for painful, blind glaucomatous eyes. Br J Ophthalmol 2001; 85(4):474-476</span>
</li>
<li id="cite_note-egbert11-11"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-egbert11_11-0">11.0</a></sup> <sup><a href="#cite_ref-egbert11_11-1">11.1</a></sup> <sup><a href="#cite_ref-egbert11_11-2">11.2</a></sup></span> <span class="reference-text">Egbert PR, Fiadoyor S, Budenz DL, et al. Diode laser transscleral cyclophotocoagulation as a primary surgical treatment for primary open-angle glaucoma. Arch Ophthamol 2001; 119:345-350</span>
</li>
<li id="cite_note-ansari12-12"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-ansari12_12-0">12.0</a></sup> <sup><a href="#cite_ref-ansari12_12-1">12.1</a></sup> <sup><a href="#cite_ref-ansari12_12-2">12.2</a></sup> <sup><a href="#cite_ref-ansari12_12-3">12.3</a></sup></span> <span class="reference-text">Ansari E, Gandhewar J. Long-term efficacy and visual acuity followeing transscleral diode laser photocoagulation in cases of refractory and non-refractory glaucoma. Eye 2007; 21:936-940</span>
</li>
<li id="cite_note-:13-13"><span class="mw-cite-backlink"><a href="#cite_ref-:13_13-0">↑</a></span> <span class="reference-text">Lai JS, Tham CC, Chan JC, et al. Diode laser transscleral cyclophotocoagulation in the treatment of chronic angle-closure glaucoma: a preliminary study. J Glaucoma 2003; 12:360-364</span>
</li>
<li id="cite_note-:14-14"><span class="mw-cite-backlink"><a href="#cite_ref-:14_14-0">↑</a></span> <span class="reference-text">Yildrim N, Yalvic IS, Sahin A, et al. A comparative study between diode laser cyclophotocoagulation and the Ahmed glaucoma valve implant in neovascular glaucoma: a long-term follow-up. J Glaucoma 2009;18:192-196.</span>
</li>
<li id="cite_note-:15-15"><span class="mw-cite-backlink"><a href="#cite_ref-:15_15-0">↑</a></span> <span class="reference-text">Kosoko O, Gaasterland DE, Pollack IP et al. Long-term outcome of initial ciliary ablation with contact diode laser transscleral cyclophotocoagulation for severe glaucoma. The Diode Laser Ciliary Ablation Study Group. Ophthalmology 1996;103(8): 1294-1302</span>
</li>
<li id="cite_note-:16-16"><span class="mw-cite-backlink"><a href="#cite_ref-:16_16-0">↑</a></span> <span class="reference-text">Kirwan JF, Shah P, Khaw PT. Diode laser cyclophotocoagulation: role in the management of refractory pediatric glaucomas. Ophthalmology 2002;109(2): 316-323</span>
</li>
<li id="cite_note-:17-17"><span class="mw-cite-backlink"><a href="#cite_ref-:17_17-0">↑</a></span> <span class="reference-text">Ocakoglu O, Arslan OS, Kayiran A. Diode laser transscleral cyclophotocoagulation for the treatment of refractory glaucoma after penetrating keratoplasty. Curr Eye Res 2005; 30(7):569-574</span>
</li>
<li id="cite_note-:18-18"><span class="mw-cite-backlink"><a href="#cite_ref-:18_18-0">↑</a></span> <span class="reference-text">Scholte T, Derse M, Zierhut M. Transscleral diode laser cyclophotocoagulation for the treatment of refractory glaucoma secondary to inflammatory eye diseases. Br J Ophthalmol 2000;84(9):999-1003.</span>
</li>
<li id="cite_note-:19-19"><span class="mw-cite-backlink"><a href="#cite_ref-:19_19-0">↑</a></span> <span class="reference-text">Kumar A, Dada T, Singh RP, et al. Diode laser trans-scleral cyclphotocoagulation for glaucoma following silicone oil removal. Clin Experiment Ophthalmol 2001; 29(4):220-224</span>
</li>
<li id="cite_note-:20-20"><span class="mw-cite-backlink"><a href="#cite_ref-:20_20-0">↑</a></span> <span class="reference-text">Berke SJ. Endocyclophotocoagulation in Glaucoma Eds Shaarawy TM, Sherwood MB, Hitchings RA, and Crowston JG. Glaucoma. Vol 2. China: Saunders: 2009:(117)591-598.&#160;</span>
</li>
<li id="cite_note-lin21-21"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-lin21_21-0">21.0</a></sup> <sup><a href="#cite_ref-lin21_21-1">21.1</a></sup></span> <span class="reference-text">Lin SC. Endoscopic and transcleral cyclophotocoagulation for the treatment of refractory glaucoma. J Glaucoma 2008; 17(3):238-247</span>
</li>
<li id="cite_note-lima22-22"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-lima22_22-0">22.0</a></sup> <sup><a href="#cite_ref-lima22_22-1">22.1</a></sup> <sup><a href="#cite_ref-lima22_22-2">22.2</a></sup> <sup><a href="#cite_ref-lima22_22-3">22.3</a></sup> <sup><a href="#cite_ref-lima22_22-4">22.4</a></sup></span> <span class="reference-text">Lima FE, Magacho L, Carvalho DM, et al. A prospective, comparative study between endoscopic cyclophotocoagulation and the Ahmed drainage implant in refractory glaucoma. J Glaucoma 2004; 13(3):233-237</span>
</li>
<li id="cite_note-neely23-23"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-neely23_23-0">23.0</a></sup> <sup><a href="#cite_ref-neely23_23-1">23.1</a></sup></span> <span class="reference-text">Neely DE, Plager DA. Endocyclophotocoagulation for management of difficult pediatric glaucomas. JAAPOS 2001; 5(4):221-229</span>
</li>
<li id="cite_note-carter37-24"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-carter37_24-0">24.0</a></sup> <sup><a href="#cite_ref-carter37_24-1">24.1</a></sup></span> <span class="reference-text">Carter BC, Plager DA, Neely DE, et al. Endoscopic diode laser cyclophotocoagulation in the management of aphakic and pseudophakic glaucoma in children, J AAPOS 2007;11(1):34-40</span>
</li>
<li id="cite_note-:24-25"><span class="mw-cite-backlink"><a href="#cite_ref-:24_25-0">↑</a></span> <span class="reference-text">Nabili S, Kirkness CM. Trans-scleral diode laser cyclophoto-coagulation in the treatment of diabetic neovascular glaucoma. Eye 2004; 18(4):352-356</span>
</li>
<li id="cite_note-:25-26"><span class="mw-cite-backlink"><a href="#cite_ref-:25_26-0">↑</a></span> <span class="reference-text">Pokroy R, Greenwald Y, Pollack A, et al. Visual loss after diode laser cyclophotocoagulation for primary open-angle and neovascular glaucoma. Ophthalmic Surg Lasers Imaging 2008; 39(1):22-29.</span>
</li>
<li id="cite_note-:26-27"><span class="mw-cite-backlink"><a href="#cite_ref-:26_27-0">↑</a></span> <span class="reference-text">Bloom PA, Tasi JC, Sharma K, et al. “Cyclodiode”. Trans-scleral diode laser cyclophotocoagulaiton in the treatment of advanced refractory glaucoma. Ophthalmology 1997; 104(9):1508-1519.</span>
</li>
<li id="cite_note-:27-28"><span class="mw-cite-backlink"><a href="#cite_ref-:27_28-0">↑</a></span> <span class="reference-text">Azuara-Blanco A, Dua HS. Malignant glaucoma after diode laser laser cyclophotocoagulation. Am J Ophthalmol 1999; 127(4):467-469.</span>
</li>
<li id="cite_note-:28-29"><span class="mw-cite-backlink"><a href="#cite_ref-:28_29-0">↑</a></span> <span class="reference-text">Shen SY, Lai JS, Lam DS. Necrotizing scleritis following diode laser transscleral cyclophotocoagulation. Ophthalmic Surg Lasers Imaging 2004; 35(3):251-253.</span>
</li>
<li id="cite_note-:29-30"><span class="mw-cite-backlink"><a href="#cite_ref-:29_30-0">↑</a></span> <span class="reference-text">Bechrakis NE, Muller-Stolzenberg NW, Helbig H, Foerster MH. Sympathetic ophthalmia following laser cyclophotocoagulation. Arch Ophthalmol 1994; 112(1):80-84.</span>
</li>
<li id="cite_note-:30-31"><span class="mw-cite-backlink"><a href="#cite_ref-:30_31-0">↑</a></span> <span class="reference-text">Jonas JB, Back W, Sauder G, et al. Sympathetic ophthalmia in vater association combined persisting hyperplastic primary vitreous after cyclodestructive procedure. Eur J Ophthalmol 2006; 16(1):171-172.</span>
</li>
<li id="cite_note-chen31-32"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-chen31_32-0">32.0</a></sup> <sup><a href="#cite_ref-chen31_32-1">32.1</a></sup></span> <span class="reference-text">Chen J, Cohn RA, Lin SC, et al. Endoscopic photocoagulation of the ciliary body for the treatment of refractory glaucomas. Am J Ophthalmol 1997; 124(6):787-796.</span>
</li>
<li id="cite_note-:32-33"><span class="mw-cite-backlink"><a href="#cite_ref-:32_33-0">↑</a></span> <span class="reference-text">Gayton JL. Traumatic aniridia during endoscopic laser cycloablation. J Cataract Refract Surg 1998; 24(1):134-135.</span>
</li>
<li id="cite_note-:33-34"><span class="mw-cite-backlink"><a href="#cite_ref-:33_34-0">↑</a></span> <span class="reference-text">Rivier D, Paula JS, Kim E, et al. Glaucoma and keratoprosthesis surgery: Role of adjunctive cyclophotocoagulation. J Glaucoma 2009; 18(4):321-324.</span>
</li>
<li id="cite_note-rotchford34-35"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-rotchford34_35-0">35.0</a></sup> <sup><a href="#cite_ref-rotchford34_35-1">35.1</a></sup></span> <span class="reference-text">Rotchford AP, Jayasawal R, Madhusuhan S, et al. Transscleral diode laser cycloablation in patients with good vision. Br J Ophthalmol 2010; 94(9):1180-1183.</span>
</li>
<li id="cite_note-:35-36"><span class="mw-cite-backlink"><a href="#cite_ref-:35_36-0">↑</a></span> <span class="reference-text">Gayton JL, VanDerKarr M, Sanders V. Combined cataract and glaucoma surgery: Trabeculectomy versus endoscopic laser cycloablation. J Cataract Refract Surg 1999; 25:1214-1219.</span>
</li>
<li id="cite_note-:36-37"><span class="mw-cite-backlink"><a href="#cite_ref-:36_37-0">↑</a></span> <span class="reference-text">Francis BA, Kawji AS, Vo NT, et al. Endoscopic cyclophotocoagulation (ECP) in the management of uncontrolled glaucoma with prior aqueous tube shunt. J Glaucoma 2010Nov2. [Epub ahead of print]. </span>
</li>
</ol></div>
<!-- 
NewPP limit report
Cached time: 20230306035150
Cache expiry: 86400
Dynamic content: false
Complications: [my_variables_no_cache]
[SMW] In‐text annotation parser time: 0.001 seconds
CPU time usage: 0.207 seconds
Real time usage: 0.769 seconds
Preprocessor visited node count: 954/1000000
Post‐expand include size: 6207/2097152 bytes
Template argument size: 1227/2097152 bytes
Highest expansion depth: 11/40
Expensive parser function count: 0/100
Unstrip recursion depth: 0/20
Unstrip post‐expand size: 17956/5000000 bytes
-->
<!--
Transclusion expansion time report (%,ms,calls,template)
100.00%  255.713      1 Template:Article
100.00%  255.713      1 -total
 88.94%  227.419      4 Template:Infobox_section
 39.32%  100.544      8 Template:UserLookup
  6.30%   16.106      1 Template:Review_expired
  1.61%    4.114      1 Template:Infobox_end
  0.58%    1.481      1 Template:Get_active_contest
  0.34%    0.869      1 Template:Infobox_begin
-->
</div></div><div class="printfooter">
Retrieved from "<a dir="ltr" href="https://eyewiki.org/w/index.php?title=Cyclodestructive_Procedures_in_Treatment_of_Glaucoma&amp;oldid=69808">https://eyewiki.org/w/index.php?title=Cyclodestructive_Procedures_in_Treatment_of_Glaucoma&amp;oldid=69808</a>"</div>

						<!-- end body text -->
						<!-- data blocks which should go somewhere after the body text, but not before the catlinks block-->
						<div id='mw-data-after-content'>
	<div class="mw-cookiewarning-container"><div class="mw-cookiewarning-text"><span>The Academy uses cookies to analyze performance and provide relevant personalized content to users of our website.</span></div><form method="POST"><div class='oo-ui-layout oo-ui-horizontalLayout'><span aria-disabled='false' class='oo-ui-widget oo-ui-widget-enabled oo-ui-buttonElement oo-ui-buttonElement-framed oo-ui-labelElement oo-ui-flaggedElement-progressive oo-ui-buttonWidget'><a role='button' tabindex='0' aria-disabled='false' href='https://www.aao.org/privacy-policy' rel='nofollow' class='oo-ui-buttonElement-button'><span class='oo-ui-iconElement-icon oo-ui-iconElement-noIcon oo-ui-image-progressive'></span><span class='oo-ui-labelElement-label'>Learn more</span><span class='oo-ui-indicatorElement-indicator oo-ui-indicatorElement-noIndicator oo-ui-image-progressive'></span></a></span><span aria-disabled='false' class='oo-ui-widget oo-ui-widget-enabled oo-ui-inputWidget oo-ui-buttonElement oo-ui-buttonElement-framed oo-ui-labelElement oo-ui-flaggedElement-primary oo-ui-flaggedElement-progressive oo-ui-buttonInputWidget'><button type='submit' tabindex='0' aria-disabled='false' name='disablecookiewarning' value='OK' class='oo-ui-inputWidget-input oo-ui-buttonElement-button'><span class='oo-ui-iconElement-icon oo-ui-iconElement-noIcon oo-ui-image-invert'></span><span class='oo-ui-labelElement-label'>Accept</span><span class='oo-ui-indicatorElement-indicator oo-ui-indicatorElement-noIndicator oo-ui-image-invert'></span></button></span></div></form></div>
</div>

					</div>
					<!-- category links -->
					<div id="catlinks" class="catlinks" data-mw="interface"><div id="mw-normal-catlinks" class="mw-normal-catlinks"><a href="/Special:Categories" title="Special:Categories">Categories</a>: <ul><li><a href="/Category:Articles" title="Category:Articles">Articles</a></li><li><a href="/Category:Glaucoma" title="Category:Glaucoma">Glaucoma</a></li></ul></div></div>
				</div>
			</div>
		</div>
	</div>
	<div class="mb-2 mt-4 footer container">
		<div class="row">
			<div class="col">
				<!-- navigation bar -->
				<nav class="p-navbar not-collapsible small mb-2" role="navigation" id="mw-navigation-hbpzysjbjp">
					<div class="navbar-nav">
					<!-- toolbox -->
					<div id="t-whatlinkshere" class="nav-item"><a href="/Special:WhatLinksHere/Cyclodestructive_Procedures_in_Treatment_of_Glaucoma" title="A list of all wiki pages that link here [j]" accesskey="j" class="nav-link t-whatlinkshere">What links here</a></div>
					<div id="t-recentchangeslinked" class="nav-item"><a href="/Special:RecentChangesLinked/Cyclodestructive_Procedures_in_Treatment_of_Glaucoma" rel="nofollow" title="Recent changes in pages linked from this page [k]" accesskey="k" class="nav-link t-recentchangeslinked">Related changes</a></div>
					<div id="t-specialpages" class="nav-item"><a href="/Special:SpecialPages" title="A list of all special pages [q]" accesskey="q" class="nav-link t-specialpages">Special pages</a></div>
					<div id="t-print" class="nav-item"><a href="javascript:print();" rel="alternate" title="Printable version of this page [p]" accesskey="p" class="nav-link t-print">Printable version</a></div>
					<div id="t-permalink" class="nav-item"><a href="/w/index.php?title=Cyclodestructive_Procedures_in_Treatment_of_Glaucoma&amp;oldid=69808" title="Permanent link to this revision of the page" class="nav-link t-permalink">Permanent link</a></div>
					<div id="t-info" class="nav-item"><a href="/w/index.php?title=Cyclodestructive_Procedures_in_Treatment_of_Glaucoma&amp;action=info" title="More information about this page" class="nav-link t-info">Page information</a></div>
					</div>
				</nav>
			</div>
		</div>
		<div class="row">
			<div class="col">
				<!-- footer links -->
				<div id="footer-info" class="footer-info">
					<!-- info -->
					<div> This page was last edited on June 7, 2021, at 11:31.</div>
					<div>This page has been accessed 199,027 times.</div>
				</div>
				<!-- places -->
				<div id="footer-places" class="footer-places">
					<div><a href="/EyeWiki:Privacy_policy" title="EyeWiki:Privacy policy">Privacy policy</a></div>
					<div><a href="/EyeWiki:About" title="EyeWiki:About">About EyeWiki</a></div>
					<div><a href="/EyeWiki:General_disclaimer" title="EyeWiki:General disclaimer">Disclaimers</a></div>
				</div>
			</div>
			<div class="col">
				<!-- footer icons -->
				<div id="footer-icons" class="justify-content-end footer-icons">
					<!-- poweredby -->
					<div><a href="https://www.mediawiki.org/"><img src="/w/resources/assets/poweredby_mediawiki_88x31.png" alt="Powered by MediaWiki" srcset="/w/resources/assets/poweredby_mediawiki_132x47.png 1.5x, /w/resources/assets/poweredby_mediawiki_176x62.png 2x" width="88" height="31" loading="lazy"/></a></div>
					<div><a href="https://www.semantic-mediawiki.org/wiki/Semantic_MediaWiki"><img src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAFgAAAAfCAMAAABUFvrSAAACJVBMVEXe3t62trbLy8vGxsbAwMDX19e6urqsrKxHcEzQ0NC2tratra2oqKixsbHd3eDFxcXe3t7U1NTa2trX19fQ0NDV1dWNjY2dnZ2UlJSUlJTS0tKUlJSWlpbR0dGenp79/f38/Pz+/v7t7e3v7+/u7u7s7Oz19fX29vb6+vr7+/vz8/Pz8/P4+fnw8PD39/gWTq/09PX6+vktX7b/sg8XT7F6mc/f5OwhVrNvkMthhsfT2+j7rQ/M1eZqjcmFotPs7e9Cb722xuFResK/zOObstnu7/Grvd3M1+mNqNY6aLoaUbEaUbZWfsTk6fE2Zrnp7O8bTq0kWLQuYcpcg8Xh5/Byk83a4eukud1/nM+6yeQkWcGwwuDxnRQyYrigttvI0+gpW7XGyttLdsBni8geVLo0Z9XlkCPb4u+QqtcfVLLo7PNHcr73phFGX6HsmBnpkxg6bNwnXcbX3er19vnr7/SVrdhuhLl+j70vVqY6Xqv0oxJVcbQhV76DjKTz9ffQ2evE0OZAbbzu7/PS1uFufrDnrGgpSZjy8/SQnMFddrKuekXSiCsgTKRaaZHejy9yang3VptNaqspWbnmliy3j2/m6OzT3e7x8fL4+v3p6uwaN2re0cifqLiLiZWYhYGYb0xXYn+5g0xwiMKYpc2BcHZmW2srRXpGWIhecKfilz4+WID2+PyosMywqbGqss1aVnLZq33p1sGklZqrp7dkfr7CpY9yg59Ud6QZAAAAH3RSTlPfBN/f39/f2wDf39vV3/7N2rrEz5D5c8ONuHaPuXXDImoxqwAABO1JREFUSMe1kQdz01gQgBXaBS4w9OtHwMFSdPKTUNxkW+61xN2Je4tLHJNOGukkAUINJTzaUIbO9fr7TpLtS44DZiC5b6Sn3dW+TysJaWz4cv9eZFPZu/+bhkakYR88WqP59u3vjxzdDCT7GpCD4qNH3sEGzOhB5MCR/4PmA8j25uZ33t0A23lxff5hZTIzOrz2Ph8qK936l7i1tT7hk8DAoHNsbeLWKjPdQcZ+qvX9tHMNXca1XBDXHtL6x2Bh0HWtuXUo8oTgC1gVpcdsdpew92PUYtjwzFq+E9mJYfXxx1x5l2/l5Vhy0DW6TuyQCZcR2hnswXJM0h+203471u5WKMIE5mDpspIIO8sZTMZiIbczY6+JCaI+/sJZ38qjP28+nQjkx/mcqGJ26rW3iKg/fYphCL1jNk5WbqXI0nBnu00RJ2j9bNRp6MmFS0SYIXLuUlQ5w22qizHr5MTyy2u/3XxVvHHlwtWVa/xTCQIIlEaMzrgswzA5P9BrAciYASqNoiNdjL8b0GYAHN3AGAEgzPSQc9UtYCeyBQAMO2G9PhhzXfp9qdifSCT6Lj788QQnrvWEuNPI2um0LW0D+m4A6E4AnIZOeq7ksQuJvi6eUXRW+8EWXsxNPhkYGJiSXr7Rd1qtVp9MXHkgIurzAkdFxjrj7cmKbN4K5v8RGxT2sJMTpwBflNHhUJgBdoUylzy3TuwIDBRi0hf9p9VtbW3qk30X7q2Je1IybZq7mLVWFKTSADXPoqi9AzVorda0kKTS6KkRbSgaR1GT1h5CObYiW1GU27yc5z6F9Fn/yTYedeLi9AIA6AbgxGIxAMPZcZeUHH9cFavVfY97FaNA/DbazRZVV89/61at2BTlg1JXiFtrYoBmRyd7p6/UP0XxaSDmy4pt0jmuh8qx6wQ2MmRz18TaJCUWO9xisUVhMMsoZZDiGHLLuXUbso2iatP/1HvhYu3n3bh6Pe/LUjZSj1NUJ8lSlNwahRRlMRjmyFDICikVn8+SacomdbZTVj+0mQSxweS1WqpiHK/Ncubs858f9idOJ/qKS1cv+RbFuIbMmHEvTbO4QeF25CxyD62nSbmJ1MUzRrpiwR0RPBJMpnCGxWVGXBn8TkarNGQHjuPrxOeWY4GY9FmxWHy19Gvv+ayYF6f8oYi7i8U93bjFkYokvbhWEFu8Og2ZxrUe3NMpc3vLhqqYpVV4XbwDQkpgoVwYKOR9N5d+eXB5vJevQA0pD7oVqi4WOj16vX6EYSA08WKvyeOZJw1cQ6rsnXOa/RYoM0Kls0zLuVoHhHAHL8YFXkwVCoE8uXhvMVCY8mW5Ci8eKkcgJ9azOl0UajNDFiUpj5JeloEqTgwd/iCUJP0sFMSejkpO96b4zl1fPuYiyd6Vs4GBmHSsJoYmLy/WeBTlis5rlJYrgjhe1s+XOXGEtHJOMl4VB2EHLauKdyG7JBLIc//uslRKkhOrcGJqyiU9z5UkOpVOwiGXSyQizRAfqlRc7Y5KJFnV6FReiWSV7xAWeQd/SOSq6qY18eVHq4vjlyazEJ73ScmJPVxJVKdF9MFwYpFIEL+ehvDOcSH8YXRsAa4XfwS7kd0tLfw7Sp7fl7xJywbYjTTVotfTb+849lEcb0K+2lMN/5o+tons+Rxp+PrQ8U3n0BcNSGPj4W+bPuX5ZLNo+uxwY+PfoLJHX1KXgyMAAAAASUVORK5CYII=" alt="Powered by Semantic MediaWiki" class="smw-footer" width="88" height="31" loading="lazy"/></a></div>
				</div>
			</div>
		</div>
	</div>
<script src="https://www.googletagmanager.com/gtag/js?id=UA-64665049-1" async=""></script><script>
window.dataLayer = window.dataLayer || [];
function gtag(){dataLayer.push(arguments);}
gtag('js', new Date());
gtag('config', 'UA-64665049-1', {});
</script>

<script>(RLQ=window.RLQ||[]).push(function(){mw.config.set({"wgPageParseReport":{"smw":{"limitreport-intext-parsertime":0.001},"limitreport":{"cputime":"0.207","walltime":"0.769","ppvisitednodes":{"value":954,"limit":1000000},"postexpandincludesize":{"value":6207,"limit":2097152},"templateargumentsize":{"value":1227,"limit":2097152},"expansiondepth":{"value":11,"limit":40},"expensivefunctioncount":{"value":0,"limit":100},"unstrip-depth":{"value":0,"limit":20},"unstrip-size":{"value":17956,"limit":5000000},"timingprofile":["100.00%  255.713      1 Template:Article","100.00%  255.713      1 -total"," 88.94%  227.419      4 Template:Infobox_section"," 39.32%  100.544      8 Template:UserLookup","  6.30%   16.106      1 Template:Review_expired","  1.61%    4.114      1 Template:Infobox_end","  0.58%    1.481      1 Template:Get_active_contest","  0.34%    0.869      1 Template:Infobox_begin"]},"cachereport":{"timestamp":"20230306035150","ttl":86400,"transientcontent":false}}});mw.config.set({"wgBackendResponseTime":1140});});</script></body>
</html>